• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

    11/19/24 8:00:00 AM ET
    $IBO
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBO alert in real time by email

    HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company's future.

    Dear Impact Biomedical Inc. (IBO) Shareholders,

    We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your support, and some additional insights into why we are excited for the future and continued success of Impact BioMedical Inc!

    We are pleased to share this update on the heels of significant achievements after having just filed our quarterly report for the third quarter of 2024. Below are some of those highlights:

    Successful IPO Launch and Funding in September

    On September 16, 2024, IBO successfully launched its Initial Public Offering (IPO), raising $4.5 million in capital. The 1.5 million shares included in the IPO are freely tradable on the NYSE. The remaining 10 million shares issued and outstanding are restricted from trading until March 2025.

    This key milestone for the company provides us with resources to accelerate our research and development initiatives, expand our market presence, and enhance shareholder value. Following the IPO, our company was officially listed on the NYSE American under the ticker IBO.

    Q3 2024 Financial Performance

    For the third quarter of 2024, IBO reported net income of $4,241,000, reflecting our ability to drive value. September 30, 2024 year-to-date net income stands at $2,363,000.

    IBO has also made considerable progress in enhancing our financial stability and shareholder value. From June 30, 2024, to September 30, 2024, our shareholder equity increased from $28.26 million to $34.56 million, marking a $6.3 million increase. This represents growth of approximately $.54 per share.

    Additionally, as of the end of the third quarter, the company's cash position was approximately $2.66 million, positioning us well for investment in strategic initiatives and operational needs.

    Strategic Debt Restructuring

    As part of our ongoing efforts to optimize our capital structure, we successfully restructured our long-term debt during the third quarter. This restructuring improves our financial flexibility, enabling repayment of the debt with company equity for 24 months allowing the Company to conserve cash, which will further enhance our ability to invest in growth and innovation.

    Strategic Partnerships and Product Development

    We are also actively collaborating with strategic partners to advance the development and funding of key assets. These partnerships are critical to driving the commercialization and monetization of our cutting-edge technologies.

    Key developments with our technologies licensed to ProPhase Labs, Inc. (NASDAQ:PRPH) include:

    Equivir™:

    Development and commercialization of the Equivir™ technology, with initial application planned as a health supplement. Studies are ongoing to support potential market claims, and contingent on final results, Equivir™ will be launched in the U.S. as an e-commerce and over the counter offering.

    Linebacker™:

    This technology is under evaluation with the initial target of solid tumors (lung, colon) in oncology. Pre-clinical studies are ongoing with results projected in 2025. Assuming successful results, these efforts would advance to IND discussions and plans to initiate a phase 1 study.

    Outside of our partnership with ProPhase Labs Inc., our Laetose™ and 3F™ platforms are proven and available for immediate partnering with the potential to generate both license milestone and royalty revenue in 2025 and beyond.

    Moreover, we continue our pursuit of new products that have the potential to expand our portfolio and enhance the company's value proposition. Our teams are focused on advancing these promising initiatives in the pipeline.

    What's Next? Live CEO Webinar on November 20th at 4:30 pm ET

    The third quarter of 2024 was a period of sturdy growth and strategic progress for Impact BioMedical Inc. With the successful IPO, strong financial performance, improved balance sheet, and continued investment in innovation, we are well-positioned to drive long-term value for our shareholders. We remain committed to executing our strategic goals and look forward to updating you on our progress as it applies to all four of our core platform technologies (Linebacker, Equivir, 3F, and Laetose).

    To further this point, we are hosting a LIVE WEBINAR on November 20th at 4:30 pm eastern time where you will have the opportunity to hear directly from myself as well as Mark Suseck (COO) and Todd Macko (CFO), where we will provide a full update on the company including our anticipated milestones and plans for the rest of 2024 and beyond. Do not miss out, sign up today with the link below and you will receive a calendar invite with all of the necessary information!

    SIGN UP HERE

    Thank you again for your continued support and we look forward to keeping you up to date on all of our progress in the coming weeks …. months … quarters … and years!

    Sincerely,

    Frank D. Heuszel

    Chairman & CEO, Impact BioMedical Inc.

    November 19, 2024

    About Impact BioMedical, Inc.:

    Impact BioMedical Inc. (NYSE:IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

    Safe Harbor Disclosure:

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

    Investor Relations:

    [email protected]



    Primary Logo

    Get the next $IBO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IBO
    $PRPH

    CompanyDatePrice TargetRatingAnalyst
    ProPhase Labs Inc.
    $PRPH
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    ProPhase Labs Inc.
    $PRPH
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    ProPhase Labs Inc.
    $PRPH
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $IBO
    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

      1/14/22 6:36:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

      12/20/21 6:25:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase downgraded by Dawson James

      Dawson James downgraded ProPhase from Buy to Neutral

      10/13/21 10:48:44 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Dss, Inc. sold $249,408 worth of shares (53,300 units at $4.68) and bought $310 worth of shares (200 units at $1.55) (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      3/24/25 8:00:38 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      12/9/24 4:05:17 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      12/3/24 9:51:36 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    SEC Filings

    See more
    • ProPhase Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

      8-K - ProPhase Labs, Inc. (0000868278) (Filer)

      7/24/25 7:15:21 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ProPhase Labs, Inc. (0000868278) (Filer)

      7/23/25 8:00:24 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ProPhase Labs, Inc. (0000868278) (Filer)

      7/21/25 8:00:51 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing

      Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") today announced the closing of a private placement financing with two investors for $3 million in senior secured convertible notes with accompanying warrants to purchase shares of common stock. The notes were issued with a 20% original issue discount, are secured by the Company and subsidiary assets, and may be prepaid at any time without penalty. The notes are not convertible for the first four months after issuance. The warrants are exercisable at $0.50 per share. The transa

      7/23/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative

      UNIONDALE, NY, July 21, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced that its Board of Directors has unanimously authorized the Company's executive team to explore a potential reverse merger transaction with a digital asset-focused operating company to supplement its existing businesses.The Board has also approved a strategic treasury initiative involving the acquisition and long-term holding of select digital assets, including Bitcoin. This initiative represents management's view that a diversified treasury strategy that includes digital assets may enhance long-t

      7/21/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

      UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company me

      6/26/25 7:30:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Dss, Inc. sold $845,013 worth of shares (890,800 units at $0.95), decreasing direct ownership by 85% to 161,100 units (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      4/7/25 9:59:28 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chan Heng Fai Ambrose sold $174,020 worth of shares (351,555 units at $0.49) (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      4/7/25 5:18:49 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chan Heng Fai Ambrose sold $1,122,920 worth of shares (1,689,693 units at $0.66) (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      4/4/25 5:15:33 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    Financials

    Live finance-specific insights

    See more
    • ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

      Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

      5/20/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

      GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable. A press release detailing these results wi

      5/13/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

      GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register usin

      3/27/25 8:27:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

      A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact B

      6/23/25 7:52:44 AM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

      GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

      2/18/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      3/19/24 4:18:00 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/5/23 4:37:55 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/4/23 4:25:33 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care